BEAUTY HEALTH CO/THE (SKIN)
US88331L1089 - Common Stock
Taking everything into account, SKIN scores 2 out of 10 in our fundamental rating. SKIN was compared to 36 industry peers in the Personal Care Products industry. While SKIN seems to be doing ok healthwise, there are quite some concerns on its profitability. SKIN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SKIN had negative earnings in the past year.
In the past year SKIN has reported a negative cash flow from operations.
In the past 5 years SKIN reported 4 times negative net income.
In the past 5 years SKIN reported 4 times negative operating cash flow.
1.2 Ratios
SKIN's Return On Assets of -4.03% is on the low side compared to the rest of the industry. SKIN is outperformed by 65.71% of its industry peers.
SKIN has a Return On Equity of -47.17%. This is in the lower half of the industry: SKIN underperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.03% | ||
| ROE | -47.17% | ||
| ROIC | N/A |
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SKIN has a Gross Margin (61.43%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SKIN has declined.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SKIN has been reduced compared to 1 year ago.
SKIN has a worse debt/assets ratio than last year.
2.2 Solvency
SKIN has an Altman-Z score of 0.17. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.17, SKIN is doing worse than 82.86% of the companies in the same industry.
SKIN has a Debt/Equity ratio of 9.23. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SKIN (9.23) is worse than 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 9.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.17 |
ROIC/WACCN/A
WACC6.24%
2.3 Liquidity
SKIN has a Current Ratio of 6.56. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN has a Current ratio of 6.56. This is amongst the best in the industry. SKIN outperforms 94.29% of its industry peers.
SKIN has a Quick Ratio of 5.57. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.57, SKIN belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.56 | ||
| Quick Ratio | 5.57 |
3. Growth
3.1 Past
The earnings per share for SKIN have decreased strongly by -181.79% in the last year.
Looking at the last year, SKIN shows a very negative growth in Revenue. The Revenue has decreased by -12.94% in the last year.
The Revenue has been growing by 49.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-181.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)-12.94%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Sales Q2Q%-19.1%
3.2 Future
The Earnings Per Share is expected to decrease by -31.54% on average over the next years. This is quite bad
The Revenue is expected to grow by 6.87% on average over the next years.
EPS Next Y-225.38%
EPS Next 2Y-73.52%
EPS Next 3Y-31.54%
EPS Next 5YN/A
Revenue Next Year-14.69%
Revenue Next 2Y-3.92%
Revenue Next 3Y1.58%
Revenue Next 5Y6.87%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SKIN. In the last year negative earnings were reported.
Also next year SKIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as SKIN's earnings are expected to decrease with -31.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.52%
EPS Next 3Y-31.54%
5. Dividend
5.1 Amount
SKIN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEAUTY HEALTH CO/THE
NASDAQ:SKIN (11/21/2024, 8:00:02 PM)
After market: 1.3701 -0.02 (-1.43%)1.39
-0.1 (-6.71%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap172.53M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.03% | ||
| ROE | -47.17% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.43% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 9.23 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.56 | ||
| Quick Ratio | 5.57 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-181.79%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-225.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-12.94%
Revenue growth 3Y49.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y